Honest Criticisms and Limitations of the WHI E-alone Trial
A detailed examination of the WHI estrogen-alone trial's enrollment biases, statistical caveats, generalizability gaps, and what subsequent peer commentary revealed about its limitations.
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

Showing 8 of 8 clinical reviews.
A detailed examination of the WHI estrogen-alone trial's enrollment biases, statistical caveats, generalizability gaps, and what subsequent peer commentary revealed about its limitations.
A detailed methodology breakdown of the WHI conjugated equine estrogen trial in hysterectomized women, covering randomization, blinding, endpoint adjudication, statistical design, and how each choice shapes clinical interpretation.
How the WHI estrogen-alone trial reshaped prescribing guidelines, risk counseling, and patient selection for conjugated equine estrogen in hysterectomized women.
Health-economic analysis of the WHI estrogen-alone trial: cost per QALY estimates, payer-coverage considerations, list-price vs net-price reality for conjugated equine estrogen, and relative-value calculations for hysterectomized women.
Deep dive into the WHI conjugated equine estrogen-alone trial follow-up data, covering post-intervention outcomes for CHD, breast cancer, mortality, and what changed after median 13-year cumulative follow-up.
Complete breakdown of the WHI Estrogen-Alone trial results including hazard ratios, confidence intervals, age-stratified subgroups, and the time-course pattern across 7.1 years of follow-up.
Detailed breakdown of WHI estrogen-alone trial subgroup analyses by age, time since menopause, BMI, race/ethnicity, and baseline biomarkers, with clinical implications for prescribing conjugated equine estrogen.
A deep-dive overview of the Women's Health Initiative estrogen-alone trial (2004), covering methodology, key cardiovascular and breast cancer findings, and what they mean for HRT practice today.